We report symptomatic asthma, associated with objective and highly significant increases in both airway responsiveness and airflow limitation, presenting de novo in a male patient 6 weeks after suddenly discontinuing lithium carbonate therapy.
- adverse drug reaction
Statistics from Altmetric.com
Increased mortality from asthma in both those who use or have recently used major tranquillizers has recently been described.1 2 Conversely, improvement in asthma control has been reported during the treatment of schizo-affective disorders with lithium carbonate.3 We have recently observed symptomatic asthma presenting de novo in a male patient 6 weeks after suddenly discontinuing lithium carbonate therapy, and 3 months after he was recruited into an epidemiological survey of asthma prevalence in the general population.
A 37-year-old man, a lifelong non-smoker, had no respiratory symptoms, had never been diagnosed as having asthma, and had never taken anti-asthma therapy. He suffered from a bipolar schizo-affective disorder and had received oral lithium carbonate 1400 mg with sulpiride 600 mg daily for 14 years. The serum lithium was well within the recommended therapeutic range. Airway responsiveness was quantified during the survey by a PD20 of 291 μg (the cumulative provoking dose of inhaled methacholine responsible for a 20% decrement in FEV1).4PD20 values of less than 200 μg are generally associated with other evidence of active asthma, whereas values greater than 1000 μg are almost never associated with active disease. Values of 200–1000 μg represent a ‘grey zone’ where some subjects are symptomatic and some are not. Allergen skin prick tests were negative but serum total IgE was mildly elevated at 130 kU/l (normal <100).
Six weeks later he was noted to have an asymptomatic bradycardia (resting pulse rate of 44 beats/min) and lithium therapy was discontinued on the advice of a cardiologist, thyroid function proving to be normal. After a further 6 weeks he complained of nocturnal cough and exertional wheeze. Percentage predicted FEV1 had fallen from 112 to 66% and airway responsiveness had increased markedly (PD20 from 291 to 9 μg of methacholine). There was no evidence of intercurrent respiratory infection. The diagnostic use of a further lithium challenge was considered inappropriate in view of the previous bradycardia, and he was commenced on inhaled budesonide and terbutaline. This resulted in a rapid symptomatic and physiological improvement (figure). Within 4 weeks the FEV1 had improved to 3.74 litres (100% predicted) and the PD20 had increased to 214 μg (a 24-fold increase). Several months later the patient's mental state deteriorated and he discontinued his inhaled therapy with a subsequent increase in airway responsiveness and asthma symptoms.
The development of asthma following cessation of lithium therapy has not, to our knowledge, been described before, nor has it been reported to the UK Committee on Safety of Medicines (personal communication). The relationship is biologically plausible, however, and the onset of asthmatic symptoms in our patient within 6 weeks of discontinuing lithium medication was associated with objective and highly significant increases in both airway responsiveness and airflow limitation. It was fortunate that baseline measurements had, by chance, been obtained only 3 months earlier at the time of our survey. The baseline level of airway responsiveness had been in the ‘grey zone’ where some subjects have mild symptoms but others do not, and so it is likely that our patient was rather more susceptible to developing asthma than the average subject without respiratory symptoms.
Improvement in asthma control during the course of lithium therapy has been recorded, and a double-blind trial of short-term lithium therapy in patients with asthma has shown an improvement in airway responsiveness.3 5 Furthermore, in vitro studies have shown that lithium partially inhibits the contractile response of airway smooth muscle, possibly by an effect on the inositol phospholipid-derived second messenger system.6 There is also evidence that lithium may influence intracellular concentrations of potassium, calcium and sodium, and there are conflicting data relating dietary sodium to airway responsiveness.7 8 There are consequently a number of mechanisms which might explain the phenomenon we have observed.
Adverse effects of lithium therapy
neurological: drowsiness, lethargy, headache, memory impairment, fine tremor
cardiovascular: conduction defects, T-wave changes
renal: thirst, polyuria, nephrogenic diabetes insipidus
gastrointestinal: nausea, vomiting, diarrhoea
endocrine: hypothyroidism, hypoparathyroidism, hyperglycaemia
miscellaneous: leucocytosis, skin rash, weight gain
lithium is a psychotropic drug which significantly improves airway responsiveness and asthma
there is, nevertheless, a documented increase in respiratory mortality in patients using other psychotropic and antidepressant agents
careful monitoring of asthma control is advisable when discontinuing lithium in patients with asthma
altered sinus node function is a well established but uncommon adverse effect of lithium therapy
altered cellular sodium transport may be the mechanism for both cardiac effects and changes in airway smooth muscle tone
Bradyarrhythmias are well recognised to complicate lithium therapy even at therapeutic levels, with reduction in membrane depolarisation rate and attenuated electrical impulse propagation as the likely primary cause. Clinically significant sinus node dysfunction is uncommon, however, and in one study of a pacemaker population lithium treatment was noted with a prevalence of only 0.46%.9 The adverse effect on asthma, a common disorder in the population at large, from lithium withdrawal may consequently prove to be a more important complication of lithium therapy in epidemiological terms than the well-recognised cardiac complications. Careful monitoring of asthma control is advisable when discontinuing lithium carbonate.